Page last updated: 2024-11-07

lacto-n-neotetraose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lacto-N-neotetraose: binds human cold agglutinin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121853
SCHEMBL ID19125559
SCHEMBL ID21048988
MeSH IDM0060568

Synonyms (17)

Synonym
13007-32-4
lacto-n-neotetraose
n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5r,6s)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetami
by63n40b1l ,
unii-by63n40b1l
d-glucose, o-beta-d-galactopyranosyl-(1-4)-o-2-(acetylamino)-2-deoxy-beta-d-glucopyranosyl-(1-3)-o-beta-d-galactopyranosyl-(1-4)-
neolactotetraose
glucopyranose, o-.beta.-d-galactopyranosyl-(1->4)-o-2-acetamido-2-deoxy-.beta.-d-glucopyranosyl-(1->3)-o-.beta.-d-galactopyranosyl-(1->4)-, d-
n-neotetraose
d-glucose, o-.beta.-d-galactopyranosyl-(1->4)-o-2-(acetylamino)-2-deoxy-.beta.-d-glucopyranosyl-(1->3)-o-.beta.-d-galactopyranosyl-(1->4)-
n-[(2s,3r,4r,5s,6r)-2-{[(2r,3s,4s,5r,6s)-3,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxy}oxan-4-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]a
DTXSID10926585
SCHEMBL19125559
SCHEMBL21048988
Q27274961
HY-N9445
CS-0173195

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Oral administration up to 5000 mg/kg bw/day to rats over 90 days was not associated with any adverse effects, based on clinical observations, body weight gain, feed consumption, clinical pathology, organ weights and histopathology findings."( Pre-clinical safety assessment of the synthetic human milk, nature-identical, oligosaccharide Lacto-N-neotetraose (LNnT).
Constable, A; Coulet, M; Marsden, E; Phothirath, P; Schilter, B, 2013
)
0.61
" There were no compound-related adverse effects in the 90-day study; therefore, 4000 mg/kg bw/day (the highest feasible dose) was established as the no-observed-adverse-effect-level."( Preclinical safety evaluation of the human-identical milk oligosaccharide lacto-N-tetraose.
Baldwin, N; Gilby, B; Lynch, B; Mikš, MH; Phipps, KR; Röhrig, CH; Šoltesová, A; Stannard, DR, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Items)

ItemProcessFrequency
Laits 1er âgecore-ingredient1
Laits pour bébécore-ingredient1
Aliments pour bébécore-ingredient1

Research

Studies (112)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (8.04)18.7374
1990's16 (14.29)18.2507
2000's14 (12.50)29.6817
2010's41 (36.61)24.3611
2020's32 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.47 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index54.68 (26.88)
Search Engine Supply Index1.97 (0.95)

This Compound (39.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (5.31%)5.53%
Reviews8 (7.08%)6.00%
Case Studies2 (1.77%)4.05%
Observational0 (0.00%)0.25%
Other97 (85.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]